focus -WSS

focus

author：Wikipedia 2025-10-01 14:19:47 - browse：6632

Boxes of Wegovy — pharma coverage from STAT — Carsten Snejbjerg/Bloomberg

LONDON — The investment arm of Novo Nordisk’s parent foundation is buying drug manufacturer Catalent in a $16.5 billion deal, an acquisition that will give Novo additional sites as it builds up production of its booming obesity and diabetes drugs.

Under the deal, Novo Holdings is purchasing Catalent, a major contract development and manufacturing company with more than 50 sites globally. In turn, Novo Nordisk is buying three of Catalent’s fill-finish sites from the investment group for $11 billion. Novo Holdings manages the assets of the Novo Nordisk Foundation, which has a controlling stake in the pharmaceutical company.

Catalent has been involved in the production of Novo’s obesity treatment Wegovy. With the agreement, Novo will pick up sites that focus on filling drugs in Italy, Brussels, and Bloomington, Ind. All have already been doing work for Novo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Researchers tackle phage therapy hurdles for wider adoption

explore

WSS

New study raises questions about niacin and heart health

MD Anderson's Padmanee Sharma responds to research credit suit

FDA warns medical device makers about rise in fabricated data

New study raises questions about niacin and heart health

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

leisure time

focus

knowledge

23andMe had bad news about my health. I wish a person had delivered it

Opioid cravings were reduced by anti

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

As AI regulations shape up, health tech startups beg for clarity

In age of alternative facts, a scholarly course on calling out crap

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Psychedelics group wrestles with new pharma identity

Infant mortality in U.S. rose last year for first time in decades: CDC

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Opioid cravings were reduced by anti

entertainment

Weight loss drugs aren’t covered by Obamacare. That may change

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Readout LOUD podcast: ESMO highlights & Roivant's big deal

New study raises questions about niacin and heart health

Researchers tackle phage therapy hurdles for wider adoption

Weight loss drugs aren’t covered by Obamacare. That may change

explore

hotspot

explore

Wikipedia